Skip to main content

ENDRA Life Sciences Inc.

For the period ended May 27, 2026. Filed May 28, 2026.

View on SEC.gov

About this filing

A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.

May 27, 2026 · Filed May 28, 2026

Use the contents to explore the available documents and sections.

NDRA$4.73-5.5%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Forward-Looking Statements

All statements in this Current Report on Form 8-K that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as “approximate,” “anticipate,” “attempt,” “believe,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “hope,” “intend,” “may,” “plan,” “possible,” “potential,” “project,” “seek,” “should,” “will,” “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Each forward-looking statement contained in this Current Report on Form 8-K is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others: our limited commercial experience, limited cash and history of losses; our ability to obtain adequate financing to fund our business operations in the future; our ability to maintain compliance with Minimum Stockholders’ Equity Requirement and the risk that the Panel disagrees with our belief that we have regained compliance with such rule; the likelihood of our entry into any definitive agreement in respect of a strategic alternative and related requirement to pay the Payment Obligation; and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this Current Report on Form 8-K speak only as of the date of filing, and the Company assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.Description
4.1Form of Common Warrant
4.2Form of Prefunded Warrant
10.1Form of Securities Purchase Agreement, dated as of May 27, 2026, between ENDRA Life Sciences Inc, and the purchaser party thereto
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.